• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Gliosarcoma - Pipeline Review, H2 2012 Product Image

Gliosarcoma - Pipeline Review, H2 2012

  • ID: 2366428
  • December 2012
  • 86 pages
  • Global Markets Direct

Gliosarcoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Gliosarcoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Gliosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gliosarcoma. Gliosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gliosarcoma.
- A review of the Gliosarcoma products under development by companies and universities/research institutes based on information derived from READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 6
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Gliosarcoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Gliosarcoma 9
Gliosarcoma Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Gliosarcoma Therapeutics – Products under Investigation by Universities/Institutes 17
Gliosarcoma – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Sorafenib + Temozolomide + Radiation Therapy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Dasatinib + Erlotinib - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Zactima + Temodar + Radiation Therapy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MLN-518 + Bevacizumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Bevacizumab + Temozolomide - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Bevacizumab + Irinotecan - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 36
Avastin + Temozolomide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Avastin + Temozolomide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BAY 43-9006 + R115777 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Temozolomide + Carmustine + O6-Benzylguanine + Filgrastim + Autologous Hematopoietic Stem Cell Transplantation + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
Zactima + Etoposide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Temodar + Topotecan - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Bevacizumab + Irinotecan - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Bevacizumab + Temozolomide - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AMG 102 + Avastin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Bevacizumab + Temozolomide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Avastin + Radiation Therapy + Temozolomide + Topotecan - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Avastin + Temozolomide + Irinotecan - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Tarceva + Temodar + Radiation Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Temozolomide + R115777 + Radiation Therapy - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 61
Imatinib Mesylate + Temozolomide - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
BAY 43-9006 + OSI-774 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BAY 43-9006 + OSI-774 + R-115777 + CCI-779 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Bevacizumab + Erlotinib + Temozolomide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
temozolomide - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Procarbazine + Lomustine + Vincristine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
temozolomide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Aflibercept + Temozolomide + Radiation Therapy - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
bevacizumab + cediranib maleate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
lapatinib ditosylate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Montanide ISA-51 + SVN53-67/M57-KLH + GM-CSF - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
nintedanib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Gliosarcoma Therapeutics – Drug Profile Updates 79
Gliosarcoma Therapeutics – Discontinued Products 81
Gliosarcoma Therapeutics - Dormant Products 82
Gliosarcoma – Product Development Milestones 83
Featured News & Press Releases 83
Jun 06, 2011: New Data From Phase II Brain Cancer Study With Prophage Series G-200 Shows Improved Overall Survival 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
Number of Products Under Development for Gliosarcoma, H2 2012 9
Products under Development for Gliosarcoma – Comparative Analysis, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 18
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Gliosarcoma Therapeutics – Drug Profile Updates 79
Gliosarcoma Therapeutics – Discontinued Products 81
Gliosarcoma Therapeutics – Dormant Products 82

List of Figures
Number of Products under Development for Gliosarcoma, H2 2012 9
Products under Development for Gliosarcoma – Comparative Analysis, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos